Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pulmonx's change in inventory for the quarter that ended in Jun. 2026 was $-0.25 Mil. It means Pulmonx's inventory
increased by $0.25 Mil
from Mar. 2026 to Jun. 2026 .
Pulmonx's change in inventory for the fiscal year that ended in Dec. 2025 was $-0.77 Mil. It means Pulmonx's inventory
increased by $0.77 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Pulmonx's Days Inventory for the quarter that ended in Jun. 2026 was 297.55.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Pulmonx's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.31.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pulmonx's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.72.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pulmonx's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulmonx Change In Inventory Related Terms
Pulmonx Change In Inventory Historical Data
* Premium members only.
The historical data trend for Pulmonx's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $-3.04 Mil mean?
Pulmonx (LUNG) has a Change In Inventory of $-3.04 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Pulmonx and its competitors.
Is Pulmonx's Change In Inventory too high?
Pulmonx's current Change In Inventory is $-3.04 Mil. Overall, Pulmonx has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's Change In Inventory compare to SRTS and SNWV?
Pulmonx's Change In Inventory of $-3.04 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Medical Devices & Instruments company?
A good Change In Inventory depends on the Medical Devices & Instruments industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Pulmonx and its competitors. Pulmonx's current Change In Inventory is $-3.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (LUNG) is currently considered Possible Value Trap. The stock's GF Value™ is $6.53, compared to a current price of $2.09 — trading 68.1% below its estimated fair value. The current Change In Inventory is $-3.04 Mil. Pulmonx's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Pulmonx (LUNG), the current Change In Inventory is $-3.04 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulmonx (LUNG) Overvalued in 2026?
Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued.
The current stock price of $2.09 is trading 68.1% below its estimated GF Value™ of $6.53.
GuruFocus considers Pulmonx to be Possible Value Trap.
Key valuation signals for LUNG:
Change In Inventory: $-3.04 Mil
GF Value™: $6.53 vs. price of $2.09 (68.1% below fair value)
No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
53GF Score
Get the complete analysis for LUNG
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUNG has been successfully added to your 
